论文部分内容阅读
目的观察蚓激酶联合奥扎格雷治疗急性脑梗塞的疗效。方法选择2009年10月～2011年5月发病的急性脑梗塞患者60例,将其随机分为对照组和治疗组各30例。两组均使用降压、降糖药物,禁用抗凝药物。对照组应用奥扎格雷80毫克,一日两次静脉滴注。治疗组加服百奥蚓激酶(北京百奥药业有限责任公司生产),每次2粒(60万单位),1日3次,治疗15天。依据临床疗效判定标准进行评分。结果蚓激酶组基本治愈率33.3%,总有效率93.3%;对照组分别为30.0%及73.3%,差异有显著意义;蚓激酶治疗组不仅神经功能恢复程度明显优于对照组,而且病人的凝血指标Fbg和血小板聚集率显著改善。不良反应少,仅2例出现黑便,停药后即恢复正常。结论蚓激酶对脑梗塞有较好疗效。
Objective To observe the efficacy of lumbrokinase combined with ozagrel in the treatment of acute cerebral infarction. Methods Sixty patients with acute cerebral infarction who developed from October 2009 to May 2011 were randomly divided into control group and treatment group, 30 cases each. Both groups used antihypertensive drugs, antidiabetic drugs. The control group was given Ozagrel 80 mg intravenously twice a day. The treatment group plus servings hundreds of Lumbrokinase (Beijing Bio-Pharmaceutical Co., Ltd. production), each 2 (60 million units), 3 times on the 1st, the treatment of 15 days. Score according to clinical efficacy criteria. Results The basic cure rate of lumbrokinase group was 33.3% and the total effective rate was 93.3%. The control group was 30.0% and 73.3% respectively. There was significant difference between the two groups. Not only the recovery of neurological function in lumbrokinase group was better than that of the control group, The index Fbg and platelet aggregation rate were significantly improved. Adverse reactions, only two cases of melena, stop after returning to normal. Conclusion Lumbrokinase has a good effect on cerebral infarction.